Praxis Precision Medicines starts trading on NASDAQ
Cambridge, Massachusetts-based Praxis Precision Medicines, a developer of treatments for central nervous system disorders, has raised about $190 million for its IPO after pricing 10 million shares at $19 per share.
16 October 2020•2 mins read
